{"analyses":[{"ciLowerLimit":"0.454","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.740","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.9","upperLimit":"14.5","value":"12.4"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"8.7","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days","title":"Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation","type":"SECONDARY","unitOfMeasure":"Months"}